BIOLASE (NASDAQ:BIOL – Get Free Report)‘s stock had its “speculative buy” rating reiterated by equities researchers at Benchmark in a research note issued on Monday, Benzinga reports. They presently have a $0.40 price objective on the medical technology company’s stock.
Other equities analysts also recently issued research reports about the stock. Maxim Group downgraded shares of BIOLASE from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 24th. StockNews.com began coverage on BIOLASE in a report on Thursday. They set a “sell” rating on the stock.
View Our Latest Stock Report on BIOLASE
BIOLASE Trading Up 7.3 %
BIOLASE (NASDAQ:BIOL – Get Free Report) last released its earnings results on Monday, May 13th. The medical technology company reported ($0.36) earnings per share (EPS) for the quarter. BIOLASE had a negative net margin of 43.56% and a negative return on equity of 1,782.73%. The firm had revenue of $10.13 million during the quarter.
Hedge Funds Weigh In On BIOLASE
An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC grew its stake in shares of BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the period. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.79% of the company’s stock.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
See Also
- Five stocks we like better than BIOLASE
- Business Services Stocks Investing
- How to Invest in Silver: A Beginner’s Guide
- What is the Shanghai Stock Exchange Composite Index?
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.